non-small cell lung cancer

Xalkori

Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer

Fri, 10/19/18 - 09:05 am

Xalkori

Pfizer nabs fast OK for a new frontline lung cancer drug as pharma giant shows off its new R&D strategy

Endpoints

Fri, 09/28/18 - 10:27 am

Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer

CP Wire

Tue, 09/25/18 - 11:50 am

MedImmune

Imfinzi

Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer

Tue, 09/25/18 - 09:51 am

Imfinzi

Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer

CP Wire

Tue, 09/25/18 - 09:42 am

Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer

Tue, 09/25/18 - 09:33 am

Another Precision Step for Roche as Ignyta Drug Heads to Regulators

Xconomy

Mon, 09/24/18 - 03:32 pm

How Tesaro Hopes to Tackle Lung Cancer

Motley Fool

Fri, 09/7/18 - 11:07 am

Tesaro

TSR-042

AstraZeneca gets further approval for Tagrisso in Japan

Pharmaforum

Tue, 08/21/18 - 10:08 am

Japan

Tagrisso

Immunicum AB Announces FDA Approval to Expand Ph Ib/II trial of Cancer Drug

CP Wire

Mon, 07/23/18 - 10:12 am

gastric cancer

Is Roche's latest Tecentriq win really a win for Merck's Keytruda?

Fierce Pharma

Thu, 07/19/18 - 11:14 am

Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors

CP Wire

Thu, 07/12/18 - 09:17 am

Seattle Genetics

colorectal cancer

FDA Grants Priority Review to Keytruda Combination Therapy for Metastatic Squamous Non-Small Cell Lung Cancer

CP Wire

Mon, 07/2/18 - 09:21 am

Merck

Keytruda

metastatic squamous non-small cell lung cancer

priority review

FDA

Advaxis Doses First Patient With Customized Immunotherapy Targeting Personal Neoantigens

CP Wire

Mon, 06/11/18 - 09:37 am

Advaxis

ADXS-NEO

immunotherapy

immunotherapy combinations

clinical trials

ASCO18: 3 unanswered questions from oncology's largest conference

Biopharma Dive

Thu, 06/7/18 - 09:35 am

FDA Grants Pfizer's Xalkori Breakthrough Therapy Status for Two New Indications

Tue, 05/29/18 - 10:14 am

Pfizer

Xalkori

anaplastic large-cell lymphoma

BMY Is Rapidly Advancing Its First-Line NSCLC Research Program

Market Realist

Mon, 05/28/18 - 01:26 pm

Bristol-Myers Squibb

Opdivo

Yervoy

AstraZeneca Announces Positive Results for Imfinzi in Non-Small Cell Lung Cancer

CP Wire

Fri, 05/25/18 - 09:20 am

MedImmune

Imfinzi